文献速递介入腹部DSACTMR

对相同肝动脉区域重复进行Y90放射性栓塞的安全性与疗效

Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory.
PubMed 文献 · Br J Radiol · 2021-01-07

研究2011年3月至2019年4月间26例接受Y90玻璃微球重复经动脉放射性栓塞(TARE)治疗相同肝动脉区域复发或残留原发病的患者,重复治疗后完全缓解73%、部分缓解23%、进展4%,放射性肝病(RILD)发生率为0%,首次与重复治疗后毒性分别为19%和23%且均为CTCAE 2级,重复治疗中位生存15.0个月与单次治疗19.0个月无显著差异(P=0.485)。

要点

  • 重复TARE至相同肝动脉区域后完全缓解达73%(19/26),RILD发生率为0%。
  • 首次与重复治疗后毒性分别为19%(5/26)与23%(6/26),均为CTCAE 2级。
  • 重复治疗中位生存15.0个月与单次治疗19.0个月无显著差异(P=0.485)。

关键影像表现/征象

  • 重复治疗后肿瘤反应为完全缓解73%(19/26)、部分缓解23%(6/26)、进展4%(1/26)。

诊断标准与关键数值

  • 肿瘤反应采用mRECIST标准评估,完全缓解19/26(73%)、部分缓解6/26(23%)、进展1/26(4%)。
  • RILD发生率为0%。
  • 首次治疗毒性19%(5/26)与重复治疗毒性23%(6/26),均为CTCAE 2级。
  • 重复治疗毒性唯一显著预测因素为MELD评分升高(P=0.04)。
  • 重复治疗中位生存15.0个月(95%CI 8.8-21.1个月),仅接受单次治疗者19.0个月(95%CI 8.1-29.9个月),P=0.485。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

OBJECTIVE: To study the efficacy and safety of repeat transarterial radioembolization (TARE) to similar hepatic arterial territories.

METHODS: Between 3/2011 and 4/2019, 26 patients (25 males and 1 Female, Mean Age: 65 yo, SD: 11.7 yo, Range: 18-83.0 yo) received TARE with Y90 glass microspheres to treat recurrent or residual primary disease in similar hepatic arterial lobe or segments. Tumor response was evaluated by imaging using the modified-RECIST criteria. Incidence of RILD and adverse events were categorized by a standardized scale using the Common Terminology Criteria for Adverse Events (CTCAE) v.4.0.

RESULTS: Mean cumulative activity after the first treatment was 2.50 GBq (SD:1.04 GBq, Range:0.61-4.93 GBq) and second treatment was 2.27 GBq (SD:1.01 GBq, Range:0.92-5.46 GBq). Mean interval time between initial and repeat treatments was 9.6 months (Range: 1-53 months). Tumor responses were complete, partial, or progression in 73% (n = 19/26), 23% (n = 6/26), and 4% (n = 1/26) in repeat treatment patients, respectively. The incidence of RILD was 0%. Toxicity after first and second treatment was seen in 19% (n = 5/26) & 23% (n = 6/26) patients, respectively, and were all of CTCAE Grade 2. No significant predictors of treatment toxicity for repeat treatment were identified except increased MELD score (p = 0.04). Kaplan-Meier survival analysis in patients with repeat treatment showed a median survival of 15.0 months (95% CI 8.8-21.1 months) and 19.0 months (95% CI 8.1-29.9 months) in patients who only received one treatment with a p value of 0.485.

CONCLUSION: Repeat TARE with glass microspheres was an effective and safe treatment strategy for disease management in patients with residual or recurrent disease to the similar hepatic arterial territories without any major treatment related toxicity.

ADVANCES IN KNOWLEDGE: Although safety and efficacy of repeat radioembolism has been studied, no study has focused on repeat treatment to similar hepatic arterial territories. The current study shows that repeat treatment to the same hepatic arterial territory is as safe as single treatment to the same territory.

来源:Br J Radiol,查看原文。版权归原作者所有。

引用

  1. Badar W, Van Ha T, Zangan S, et al. Safety and efficacy of repeat Y90 radioembolization to the same hepatic arterial territory. Br J Radiol. 2021. PMID: 33411569. doi:10.1259/bjr.20200752

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。